---
document_datetime: 2025-12-08 16:33:36
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/tecartus-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: tecartus-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.8969171
conversion_datetime: 2025-12-24 16:14:05.729002
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Tecartus

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number                    | Scope                                                                                                                           | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary        |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------|
| Variation type II / EMA/VR/0000285857 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) | 13/11/2025                          |                                             | SmPC and Annex II                | Not applicable |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                            | No 1234/2008. C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of section 4.4 of the SmPC in order to add a reference statement to current institutional / national guidelines for the monitoring and management of CRS, neurologic events and ICANS. In addition, the MAH took the opportunity to introduce clarification and administrative updates across the PI, including Annex II.   |            |            |             |           |
|----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------|
| PSUR / EMA/PSUR/0000268989 | - - In view of available data on status epilepticus from clinical trials, spontaneous reports including in some cases a close temporal relationship, and in view of a plausible mechanism of action, the PRAC considers a causal relationship between brexucabtagene autoleucel and status epilepticus is at least a reasonable possibility. The PRAC concluded that the product information of products containing brexucabtagene autoleucel should be amended accordingly.                                                                                          | 18/09/2025 | 17/11/2025 | SmPC and PL | Variation |

<div style=\"page-break-after: always\"></div>

| Renewal - 1 year / EMA/R/0000278705   | - Renewal - Accepted Renewal of marketing authorisation                                                                                                                                                                                                                                                                                                                                                                    | 18/09/2025   | 17/11/2025   |                        | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Tecartus, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion.   |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000255932 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.f.1 Change in the shelf-life or storage conditions of the finished product - B.II.f.1.c Change in storage conditions for biological medicinal products, when the stability studies have not been performed in accordance with an approved stability protocol - Accepted | 24/07/2025   | 17/11/2025   | SmPC, Labelling and PL | The SmPC section 6.4 has been updated as follows: Yescarta/Tecartus may be stored a single time at - 80 °C (± 10 °C), for up to 90 days. After storage at -80 °C (± 10 °C), the product must be used within the 90-day period or the labelled expiration date, whichever comes first. After these dates, the product must not be used and must be discarded. The Labelling and Package Leaflet have been updated accordingly.                                                        |
| Variation type IB / EMA/VR/0000265127 | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. A. ADMINISTRATIVE CHANGES - A.4 Change                                                                                                                                                                                                                             | 12/06/2025   | N/A          |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

|                                       | in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.z Other changes - Accepted   |            |            |          |                                                                                                                                                                                                                                                            |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000257524 | C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.b Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment by the competent authority is required* - Accepted Submission of the 57-month follow-up results from study ZUMA-3 (KTE-C19-103)                                                                                                                                                                                                                                                                            | 22/05/2025 | 17/11/2025 | Annex II | The results of the 57-month analysis are consistent with the results reported in the Primary Analysis clinical study report (CSR) and the prior CSR addenda. No new safety signals were identified. The benefit-risk balance of Tecartus remains positive. |

<div style=\"page-break-after: always\"></div>

|                                       | listed as a Specific Obligation in the Annex II of the Product Information. This is a phase 1/2 open-label study evaluating the safety and efficacy of brexucabtagene autoleucel in adult participants with relapsed/refractory B- precursor acute lymphoblastic leukemia (r/r ALL). The Annex II is updated accordingly.                                                                                                                                                                                            |            |     |                |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------|
| Variation type II / EMA/VR/0000242383 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.d Substantial change to or replacement of a biological/ immunological/ immunochemical test method or a method using a biological reagent for a biological active substance - Accepted - - Accepted | 27/03/2025 | N/A | Not applicable |